Kesimpta 20 mg solution for injection in pre-filled pen
Sponsors
Novartis Pharma AG, Kyverna Therapeutics Inc., Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S, Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Conditions
Multiple sclerosisPrimary or Secondary Progressive Multiple SclerosisRelapsing Remitting Multiple SclerosisRelapsing multiple sclerosis (RMS)relapsing multiple sclerosis (RMS)
Phase 2
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
Not yet recruitingCTIS2024-511168-10-00
Target: 88Updated: 2024-10-07
NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY
RecruitingCTIS2024-515470-26-00
Start: 2024-10-31Target: 90Updated: 2025-11-17
PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.
WithdrawnCTIS2025-520955-10-00
Target: 210Updated: 2025-10-20
Phase 3
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.
CompletedCTIS2023-507493-41-00
Start: 2020-08-04End: 2024-09-27Target: 293Updated: 2024-07-24
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Active, not recruitingCTIS2023-507906-15-00
Start: 2019-01-30Target: 963Updated: 2025-11-14